PortalPublikationenLow-dose or -number of BCG in non-muscle invasive bladder ca...

Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis

Standard

Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis. / Kawada, Tatsushi; Yanagisawa, Takafumi; Bekku, Kensuke; Laukhtina, Ekaterina; von Deimling, Markus; Majdoub, Muhammad; Chlosta, Marcin; Pradere, Benjamin; Babjuk, Marek; Gontero, Paolo; Moschini, Marco; Araki, Motoo; Shariat, Shahrokh F.

in: IMMUNOTHERAPY-UK, Jahrgang 15, Nr. 12, 08.2023, S. 933-943.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Kawada, T, Yanagisawa, T, Bekku, K, Laukhtina, E, von Deimling, M, Majdoub, M, Chlosta, M, Pradere, B, Babjuk, M, Gontero, P, Moschini, M, Araki, M & Shariat, SF 2023, 'Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis', IMMUNOTHERAPY-UK, Jg. 15, Nr. 12, S. 933-943. https://doi.org/10.2217/imt-2022-0309

APA

Kawada, T., Yanagisawa, T., Bekku, K., Laukhtina, E., von Deimling, M., Majdoub, M., Chlosta, M., Pradere, B., Babjuk, M., Gontero, P., Moschini, M., Araki, M., & Shariat, S. F. (2023). Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis. IMMUNOTHERAPY-UK, 15(12), 933-943. https://doi.org/10.2217/imt-2022-0309

Vancouver

Kawada T, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Majdoub M et al. Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis. IMMUNOTHERAPY-UK. 2023 Aug;15(12):933-943. https://doi.org/10.2217/imt-2022-0309

Bibtex

@article{9add7fe28724413a99a762ab3d9f1dfb,
title = "Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis",
abstract = "Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.",
author = "Tatsushi Kawada and Takafumi Yanagisawa and Kensuke Bekku and Ekaterina Laukhtina and {von Deimling}, Markus and Muhammad Majdoub and Marcin Chlosta and Benjamin Pradere and Marek Babjuk and Paolo Gontero and Marco Moschini and Motoo Araki and Shariat, {Shahrokh F}",
year = "2023",
month = aug,
doi = "10.2217/imt-2022-0309",
language = "English",
volume = "15",
pages = "933--943",
journal = "IMMUNOTHERAPY-UK",
issn = "1750-743X",
publisher = "Future Medicine Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis

AU - Kawada, Tatsushi

AU - Yanagisawa, Takafumi

AU - Bekku, Kensuke

AU - Laukhtina, Ekaterina

AU - von Deimling, Markus

AU - Majdoub, Muhammad

AU - Chlosta, Marcin

AU - Pradere, Benjamin

AU - Babjuk, Marek

AU - Gontero, Paolo

AU - Moschini, Marco

AU - Araki, Motoo

AU - Shariat, Shahrokh F

PY - 2023/8

Y1 - 2023/8

N2 - Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.

AB - Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.

U2 - 10.2217/imt-2022-0309

DO - 10.2217/imt-2022-0309

M3 - SCORING: Review article

C2 - 37409426

VL - 15

SP - 933

EP - 943

JO - IMMUNOTHERAPY-UK

JF - IMMUNOTHERAPY-UK

SN - 1750-743X

IS - 12

ER -